EMFAT
PTGX icon

Emerald Mutual Fund Advisers Trust’s Protagonist Therapeutics PTGX Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-76,965
Closed -$3.45M – 233
2021
Q2 		$3.45M Buy
+76,965
New +$2.54M 0.11% 146

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's PTGX Position: Q3 2021 in Review

Emerald Mutual Fund Advisers Trust sold out of Protagonist Therapeutics (PTGX) in Q3 2021, closing a stake of 76,965 shares — an estimated $3.45M sold.

Emerald Mutual Fund Advisers Trust first reported a position in PTGX in Q2 2021 and held it in 1 quarter. The position peaked at $3.45M in Q2 2021. 132 funds tracked by Wall St. Rank hold PTGX as of Q3 2021.

  • Emerald Mutual Fund Advisers Trust reported no remaining Protagonist Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Emerald Mutual Fund Advisers Trust sold 76,965 Protagonist Therapeutics shares in Q3 2021, an estimated $3.45M.
  • Emerald Mutual Fund Advisers Trust first reported a position in Protagonist Therapeutics in Q2 2021 and held it in 1 quarter.
  • Emerald Mutual Fund Advisers Trust's Protagonist Therapeutics position peaked at $3.45M in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2021.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q3 2021, filed 28 Oct 2021.